TRIAL OF LIVE (PRIVATE) RECOMBINANT CANARYPOX ALVA-HIV VCP205 IN HIV

活体（私人）重组金丝雀痘 ALVA-HIV VCP205 在 HIV 中的试验

• 批准号: 6115484
• 负责人: Susan Buchbinder
• 金额: $ 3.1万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115484
• 关键词: AIDS education /prevention; AIDS therapy; AIDS vaccines; HIV infections; clinical research; clinical trial phase I; disease /disorder proneness /risk; high risk behavior /lifestyle; human subject; human therapy evaluation

The specific aims of the study are to: (1) evaluate the safety and describe the reactogenicity of two candidate HIV-1 vaccines administered simultaneously: ALVAC vCP205 and SF-2 rgp 120; (2) evaluate the humoral and cellular immunogenicity of this combination of vaccines; (3) compare reactogenicity and immunogenicity of this combination of two candidate vaccines in individuals at lower risk and higher risk of HIV-1 infection; (4) assess the feasibility of conducting preventive HIV-1 vaccine efficacy trials in high risk populations through the existing HIVNET structure, including the ability to recruit and retain a diverse cohort of high risk individuals into preventive HIV-1 vaccine trials; and (5) evaluate potential behavioral and social risks to study participants in preventive HIV-1 vaccine trials.

研究的具体目的是：（1）评价安全性， 描述了两种候选HIV-1疫苗的反应原性 同时：ALVAC vCP 205和SF-2 rgp 120;（2）评价体液免疫 和细胞免疫原性;（3）比较 这两种候选物组合的反应原性和免疫原性 在HIV-1感染风险较低和较高的个体中接种疫苗; (4)评估进行预防性HIV-1疫苗效力的可行性 通过现有的HIVNET结构在高危人群中进行试验， 包括招募和留住高风险的多样化群体的能力， 预防性HIV-1疫苗试验;（5）评估 潜在的行为和社会风险，研究参与者在预防 HIV-1疫苗试验。